Navigation Links
Moffitt researchers develop new way to combat drug resistance for melanoma patients

TAMPA, Fla. (June 30, 2014) Moffitt Cancer Center researchers developed a new way to identify possible therapeutic targets for patients with drug resistant melanoma. It involves using liquid chromatography-multiple reaction monitoring mass spectrometry to measure biomarkers or molecules in blood and tissue that indicates cancer is present. These measurements can help researchers determine if a patient is responding to treatment.

Scientists have made significant strides identifying important molecules that contribute to melanoma growth and metastases, such as the proteins BRAF and MEK. Therapeutic agents that target these molecules have shown promise in the clinic, and many patients have significant reductions in tumor growth and tumor burden.

"While targeted therapy drugs, such as BRAF and MEK inhibitors, have been associated with impressive responses in melanoma patients, most patients will eventually fail therapy," said Keiran Smalley, Ph.D., associate member of the Cancer Biology and Evolution Program at Moffitt.

Tumors can develop different resistance mechanisms and adapt to targeted agents in order to survive and continue to grow. "It is likely that long-term management of melanoma patients will require combinations of drugs," said Smalley.

The molecular changes that lead to drug resistance vary between patients and each tumor. Identifying these molecular alterations with current scientific approaches is difficult, costly and time-consuming.

Smalley's team, in conjunction with the lab of John Koomen, Ph.D. of Moffitt's Chemical Biology and Molecular Medicine Program, developed a liquid chromatography-multiple reaction monitoring mass spectrometry assay to analyze more than 80 proteins known to be important in melanoma progression and resistance to targeted therapies. They showed that melanoma cells that are resistant to drugs that target MEK have alterations in a number of different cell signaling pathways. Results like this will allow for the development of new treatment strategies.

The researchers plan to expedite the identification of proteins involved in melanoma drug resistance through the use of liquid chromatography-multiple reaction monitoring mass spectrometry. The platform allows the simultaneous detection of multiple proteins in small quantities of tissue samples. It also results in highly reproducible data that can be easily validated among different laboratories.


Contact: Kim Polacek
H. Lee Moffitt Cancer Center & Research Institute

Related medicine news :

1. Moffitt study shows utilizing genetic health care professional reduces unnecessary testing
2. Moffitt researchers develop process to help personalize treatment for lung cancer patients
3. Ohio State and Moffitt form worlds largest cancer research collaboration for big data
4. Moffitt Cancer Center instrumental in new clinical guidelines for cancer-related fatigue
5. Moffitt Cancer Centers phase 3 study may be game-changer for acute myeloid leukemia
6. Moffitt Cancer Center begins Phase I clinical trial of new immunotherapy
7. Moffitt instrumental in FDA approval of revolutionary 2-drug combo to treat advanced melanoma
8. Moffitt Cancer Center launches prostate cancer study focused on black men
9. Single injection may revolutionize melanoma treatment, Moffitt study shows
10. Moffitt researchers identify gene variations that may help predict cancer treatment response
11. Moffitt Cancer Center expert standardizing guidelines for penile cancer treatment
Post Your Comments:
(Date:11/28/2015)... ... ... Trying to relax on a couch can actually be uncomfortable, so an inventor ... to personal experience with a bad back," he said. , This easy-to-use, versatile invention ... increases support. It also makes it easier to eat, do other activities and charge ...
(Date:11/27/2015)... ... 2015 , ... According to an article published November 13th on ... Washington D.C. revolved around the fact that proper dental care, both at-home and in ... link between periodontal disease (more commonly referred to as gum disease) and diabetes. According ...
(Date:11/27/2015)... ... November 27, 2015 , ... A team of Swiss doctors ... treat it. Surviving Mesothelioma has just posted the findings on the website. Click ... analyzed the cases of 136 mesothelioma patients who were treated with chemotherapy followed by ...
(Date:11/27/2015)... ... November 27, 2015 , ... The print ... USA Today in Atlanta, Dallas, New York, Minneapolis, South Florida, with a circulation ... is distributed nationally, through a vast social media strategy and across a network ...
(Date:11/27/2015)... ... November 27, 2015 , ... Intellitec Solutions ... SL User Group (MSDSLUG). Recognized as Microsoft’s official group for end users of ... SL software users, partners, industry experts and representatives. Intellitec Solutions’ membership status demonstrates ...
Breaking Medicine News(10 mins):
(Date:11/26/2015)... 2015 ) ... "Radioimmunoassay Market by Type (Reagents & Kits, ... Clinical Diagnostic Labs), Application (Research, Clinical Diagnostics), ... report to their offering. --> ... of the "Radioimmunoassay Market by Type ...
(Date:11/25/2015)...  The total global healthcare industry is expected to grow ... Latin America has the highest projected growth at ... Japan ), is second with growth projected at 11.5%. ... healthcare expenditure. In 2013-2014, total government funded healthcare was nearly ... to 41.2% in 2013-2014. In real terms, out of pocket ...
(Date:11/25/2015)... , Nov. 25, 2015  Linden Care, LLC, ... optimizing treatment outcomes for patients suffering from chronic pain, ... for a Temporary Restraining Order (TRO) enjoining Express Scripts ... two companies. --> --> ... all of its legal options. --> ...
Breaking Medicine Technology: